Eli Lilly has alerted more than 1,000 hospitals about the necessity of submitting claims data within a five-day timeframe. This action is crucial for hospitals to retain their essential price breaks under the 340B Drug Discount Program.
The urgency of this notice highlights the potential consequences for hospitals that fail to comply, which may include losing access to significant drug discounts.
This development comes amid ongoing discussions and disputes regarding the 340B program, indicating the heightened scrutiny on pharmaceutical pricing and hospital funding.
Updates
Update at 13:25 UTC on 2026-06-02
STAT reported Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks.
Sources: STAT
Update at 19:56 UTC on 2026-06-18
STAT reported Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program.
Sources: STAT
Update at 19:52 UTC on 2026-07-02
STAT reported Lawmakers step into a dispute between Eli Lilly and hospitals about the 340b drug discount program.
Sources: STAT